Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity

International Journal of Urology

Volumn 12, Issue 1, 2005, Pages 73-80

  Ouchi, Hideki ^a   Ishiguro, Hitoshi ^a   Ikeda, Naoya ^a   Hori, Mayumi ^b   Kubota, Yoshinobu ^a   Uemura, Hiroji ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANAGAWA DENTAL COLLEGE   (Japan)

Author keywords

c myc; Genistein; hTERT; Prostate cancer; Telomerase

Indexed keywords

GENISTEIN; MESSENGER RNA; MYC PROTEIN; PROTEIN P21; TELOMERASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; ONCOGENE C MYC; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TELOMERIC REPEAT AMPLIFICATION PROTOCOL;

ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; GENISTEIN; HUMANS; MALE; POLYMERASE CHAIN REACTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; TELOMERASE; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 14744304811     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2004.00973.x     Document Type: Article

References (32)

1. Donn AS, Muir CS. Prostatic cancer: Some epidemiological features. Bull. Cancer 1985; 72: 381-90.
2. Shimazu H, Ross RK, Berrnstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and White immigrants in Los Angeles County. Br. J. Cancer 1991; 63: 963-6.
3. Tominaga S. Cancer incidence in Japanese in Japan, Hawaii, and Western United States. Natl Cancer Inst. Monogr. 1985; 69: 83-92.
4. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J. Nutr. 1995; 125 (Suppl. 3): S777-83.
5. Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993; 22: 335-45.
6. Burke TR. Protein-tyrosine kinase inhibitors. Drugs Future 1992; 17: 119-31.
7. Hunter T, Cooper JA. Protein tyrosine kinases. Annu. Rev. Biochem. 1985; 54: 897-930.
8. Greider CW. Telomere length regulation. Annu. Rev. Biochem. 1996; 65: 337-65.
9. Herbert B, Pitts AE, Baker SI, Hamilton SE, Shay JW, Corey DR. Inhibition of human telomerase in immortal human cells to progressive telomere shortening and cell death. Proc. Natl Acad. Sci. USA 1999; 96: 14276-81.
10. Lin Y, Uemura H, Fujinami K, Hosaka M, Kubota Y. Telomerase activity in primary prostate cancer. J. Urol. 1997; 157: 1161-5.
11. Counter CM, Hirte HW, Bacchetti S, Harley CB. Telomerase activity in human ovarian carcinoma. Proc. Natl. Acad. Sci. USA 1994; 91: 2900-904.
12. Meyerson M, Counter CM, Eaton EN et al. hEST2, the putative human telomerase catalytic subunit gene, is upregulated in tumor cells and during immortalization. Cell 1997; 90: 785-95.
13. Takakura M, Kyo S, Kanaya T, Tanaka M, Inoue M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res. 1998; 58: 1558-61.
14. Kanaya T, Kyo S, Takakura M, Ito H, Namiki M. hTERT is a critical determinant of telomerase activity in renal cell carcinoma. Int. J. Cancer 1998; 78: 539-43.
15. Xiao YS, Cathie AP, James PH, Thomas TY, James MP. Increased UDP-glucuronosyltransferase activity and decreased prostate specific antigen production by biochnin A in prostate cancer cells. Cancer Res. 1998; 58: 2379-84.
16. Greenberg RA, O'Hagan RC, Deng H et al. Telomerase reverse transcriptase gene is a direct target of c-myc but is not functionally equivalent in cellular transformation. Oncogene 1999; 18: 1219-26.
17. Jian CS, Russel DK, Qingyi W et al. Low-dose genistein induces cyclin-dependent kinase inhibitors and G1 cell-cycle arrest in human prostate cancer cells. Mol. Carcinog. 2000; 29: 92-102.
18. Albanel J, Han W, Mellad B. Telomerase activity is repressed during differentiation of maturation-sensitive but resistant human tumor cell lines. Cancer Res. 1996; 56: 1503-508.
19. Melana SM, Holland JF, Pogo BGT. Inhibition of cell growth and telomerase activity of breast cancer cells in vivo by 3′-azido-3′- deoxythymidine. Clin. Cancer Res. 1998; 4: 693-6.
20. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW, Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Med. 1995; 1: 249-55.
21. Wu KJ, Grandori C, Amacker M et al. Direct activation of hTERT transcription by c-myc. Nat. Genet. 1999; 21: 220-24.
22. Yan CH, Chen XG, Li Y, Han R. Effect of genistein, a soybean-derived isoflavone, on proliferation and differentiation of B16-BL6 mouse melanoma cells. J. Asian Nat. Prod. Res. 1999; 1: 285-99.
23. Heruth DP, Wetmore LA, Leyva A, Rothberg PG. Influence of protein tyrosine phosphorylation on the expression of the c-myc oncogene in cancer of large bowel. J. Cell Biochem. 1995; 58: 83-94.
24. Davis JN, Singh B, Bhuiyan M, Sarkar FH. Genistein-induced upregulation of p21, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr. Cancer 1998; 32: 123-31.
25. Choi YH, Lee WH, Park KY, Zhang L. p-53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J. Cancer Res. 2000; 91: 164-73.
26. Belair CD, Yeager TR, Lopez PM, Reznikoff CA. Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc. Natl Acad. Sci. USA 1997; 94: 13677-82.
27. Buchkovich KJ, Greider CW. Telomerase regulation during entry into the cell cycle in normal human T cells. Mol. Biol. Cell 1996; 7: 1443-54.
28. Mitchell KO, El-Deiry WS. Overexpression of c-myc inhibits p21WAF/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ. 1999; 10: 223-30.
29. Blagosklonny MV, Prabhu NS, El-Deiry WS. Defects in p21WAF/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells. Cancer Res. 1997; 57: 320-25.
30. Samir AA, Olivia A, Fazlul HS. Gemstein elicits pleiotropic molecular effects on head and neck cancer cells. Clin. Cancer Res. 2001; 7: 4174-81.
31. Bektic J, Berger AP, Pfeil K, Dobler G, Bartsch G, Klocker H. Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta. Eur. Urol. 2004; 45: 245-51.
32. Davis JN, Kucuk O, Sarkar FH. Expression of prostate-specific antigen is transcriptionally regulated by genistein in prostate cancer cells. Mol. Carcinog. 2002; 34: 91-101.